Spain’s Grifols has agreed to buy U.S.-based Talecris Biotherapeutics, which makes plasma-based protein therapies, for $3.4 billion in a bold move to expand its business in blood products – Reuters
Spain’s Grifols has agreed to buy U.S.-based Talecris Biotherapeutics, which makes plasma-based protein therapies, for $3.4 billion in a bold move to expand its business in blood products – Reuters
Copyright © 2024 Wall Street Pit | Contact Us | Advertise | Terms of Use | Privacy Policy
Leave a Reply